drugset / Trial / NCT00240734
Treatment of Anemia in Diabetic Subjects With CKD
Phase 2
Terminated
11 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Ortho Biotech Products, L.P. · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to compare the proportion of subjects receiving either Epoetin alfa (PROCRIT®) or placebo who are able to achieve a hemoglobin response, defined by at least a 1 gram/deciliter increase from baseline by Week 17.
Timeline
- Start
- 2005-03
- Primary completion
- —
- Completion
- 2005-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | epoetin alfa | Protein / enzyme biologic | — | Subcutaneous |